Netflix, Inc. (NASDAQ:NFLX) has risen 75.34% since September 30, 2016 and is uptrending. It has outperformed by 58.64% the S&P500. Short shares decreased from 2,926,782 to 2,505,633 over that period. KPTI's SI was 2.51M shares in September as released by FINRA. Royal Bankshares Of Canada reported 853 shares. Days to cover decreased from 20.0 to 15.0 and the short interest percentage is 0.05% as of August 31. The short interest to Karyopharm Therapeutics Incorporated's float is 12.56%. (NASDAQ:HALL). Geode Limited Liability Company invested in 91,295 shares or 0% of the stock. About 93,078 shares traded. The value of the total investment in Karyopharm Therapeutics Inc. went from $3,531,000 to $2,715,000 a change of $816,000 quarter over quarter. It has outperformed by 4.49% the S&P500.
Since April 3, 2017, it had 0 buys, and 4 selling transactions for $497,855 activity. BARTON RICHARD N sold $318,160 worth of stock. $101,730 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares were sold by Cantley Lewis Clayton Jr. (NASDAQ:NFLX) was sold by HUNT NEIL D on Monday, May 8. Over the last quarter, insiders have sold 7,195 shares of company stock valued at $76,950. Also, there are 1 buy, 1 sell and 0 strong sell ratings, collectively assigning a 1.5 average brokerage recommendation. 93 funds opened positions while 256 raised stakes. The investment professionals in our partner's database now possess: 26.98 million shares, up from 26.17 million shares in 2017Q1.
In the latest earnings report the EPS was $-2.69 and is estimated to be $-2.67 for the current year with 47,138,000 shares presently outstanding. Shine Invest Advisory Incorporated has 0.01% invested in Netflix, Inc. The Massachusetts-based Tekla Capital Management Llc has invested 0.25% in the stock. Northern holds 0% or 175,590 shares. Chicago Equity Prtn Lc owns 102,415 shares.
Institutional investors now hold around $305 million or 66.3% in KPTI stock. Envestnet Asset reported 120 shares. New Jersey Better Educational Savings Trust stated it has 3,000 shares. Omega Advsrs reported 0.41% in Netflix, Inc. Eaton Vance has 209,902 shares for 0.08% of their portfolio. The North Carolina-based Carroll Associate Incorporated has invested 0.01% in Netflix, Inc. Tcw Group reported 40,648 shares or 0% of all its holdings. Moreover, Opus Point Partners Management Llc has 0.83% invested in the company for 100,000 shares. MLV maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) rating on Wednesday, August 12. The firm earned "Hold" rating on Wednesday, January 6 by Jefferies. The firm has "Outperform" rating given on Friday, May 27 by Raymond James.
Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. The company has market cap of $549.40 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It now has negative earnings. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
COPYRIGHT VIOLATION NOTICE: "Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Karyopharm Therapeutics (NASDAQ:KPTI) Share Price" was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. Its up 0.41, from 0.84 in 2017Q1.
Shares of Karyopharm Therapeutics (KPTI) traded up 0.92% during trading on Friday, reaching $10.98. 8 funds opened positions while 31 raised stakes. Citigroup owns 86 shares. C Grp Hldg A S holds 15,678 shares. Karyopharm Therapeutics earned a media sentiment score of 0.17 on Accern's scale. Rhumbline Advisers holds 19,185 shares or 0% of its portfolio. Northern Tru holds 405,374 shares. California Employees Retirement System stated it has 0% of its portfolio in Hallmark Financial Services, Inc.
News coverage about Karyopharm Therapeutics (NASDAQ:KPTI) has been trending somewhat positive recently, Accern Sentiment Analysis reports.
Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Leerink Swann maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) rating on Tuesday, August 11. Canaccord Genuity initiated Karyopharm Therapeutics Inc (NASDAQ:KPTI) rating on Tuesday, December 22. As per Wednesday, September 2, the company rating was initiated by JP Morgan. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the company a "buy" rating in a report on Saturday, June 24th. The firm earned "Buy" rating on Monday, September 11 by Jefferies. Swiss Retail Bank holds 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI) or 56,850 shares.